1) La descarga del recurso depende de la página de origen
2) Para poder descargar el recurso, es necesario ser usuario registrado en Universia


Opción 1: Descargar recurso

Opción 2: Descargar recurso

Detalles del recurso

Descripción

Background: Biological medicines are starting to lose their patent protection, so similar, inexact copies (biosimilars) are being developed and licensed. The high acquisition costs of biologics for healthcare providers could be reduced by switching to biosimilars, thus alleviating budgetary pressures and increasing patient access. Therefore, the acceptance of biosimilars by prescribers in Great Britain (GB; England, Scotland, Wales) needs to be described and understood. Objective: To determine uptake of the first wave of biosimilars (somatropin, epoetin, filgrastim) by local formularies (lists of preferred medicines for prescribing in local healthcare settings). Settings: This study targeted local formularies in GB. Method: In November 2014, local formularies (medicines formularies of Acute Trusts and Health Boards in GB) were screened for their approach to listing of biologics and their biosimilars as well as recommendations on usage of these pharmaceuticals. Main Outcomes Measures: Listing frequencies of biosimilars. Results: One hundred and forty-six British local formularies were screened. Amongst the 80% of formularies in which brand names were specified, biosimilar filgrastim was the most frequently listed when compared to the other targeted biosimilars. Biosimilars were listed in preference to reference biologic medicine in 49% of local formularies for filgrastim, 11% for somatropin and in only 6% for epoetin. Conclusion: Although the market for biosimilars can act in parallel to the generic market, their uptake measured using local British formularies was less than what is expected given that the British market for medicines has a strong focus on generics. Finally, geographical variability within GB requires further investigation.

Pertenece a

Faculty of Technology ePrints Service  

Autor(es)

Alnahar, Saja -  Elliott, Rachel A. -  Smith, Murray D. - 

Id.: 69957675

Idioma: inglés  - 

Versión: 1.0

Estado: Final

Tipo:  application/pdf - 

Palabras claveB200 Pharmacology, Toxicology and Pharmacy - 

Tipo de recurso: Article  -  PeerReviewed  - 

Tipo de Interactividad: Expositivo

Nivel de Interactividad: muy bajo

Audiencia: Estudiante  -  Profesor  -  Autor  - 

Estructura: Atomic

Coste: no

Copyright: sí

Formatos:  application/pdf - 

Requerimientos técnicos:  Browser: Any - 

Relación: [References] http://eprints.lincoln.ac.uk/28308/

Fecha de contribución: 29-ago-2017

Contacto:

Localización:

Otros recursos del mismo autor(es)

  1. Improving prescribing safety in general practices in the East Midlands through the Scaling Up PINCER intervention Conference presentation summarising the results of the Scaling Up PINCER intervention
  2. What is the value of specialist shoulder physiotherapy? A cost-utility analysis .
  3. Effect on hypnotic prescribing of a quality improvement collaborative for primary care of insomnia: segmented regression analysis .
  4. Effect on hypnotic prescribing of a quality improvement collaborative for primary care of insomnia: segmented regression analysis Introduction Patients with insomnia commonly present to general practice. Hypnotic misuse and underu...
  5. Benefits and Consequences for the Poor and the Disabled The new Medicare Part D will improve access to medications for millions of Americans. One subgroup o...

Otros recursos de la mismacolección

  1. The role of the mammalian prion protein in the control of sleep Sleep disruption is a prevalent clinical feature in many neurodegenerative disorders, including huma...
  2. Communist heritage representation gaps and disputes Abstract Purpose–The purpose of this paper is to identify and explore how different stakeholders rep...
  3. β-hairpin-mediated formation of structurally distinct multimers of neurotoxic prion peptides Protein misfolding disorders are associated with conformational changes in specific proteins, leadin...
  4. Tuberculosis treatment and management-an update on treatment regimens, trials, new drugs, and adjunct therapies WHO estimates that 9 million people developed active tuberculosis in 2013 and 1.5 million people die...
  5. How to match technological and social innovation: insights from the biomedical 3D printing industry The purpose of this paper is to understand the transition from technological innovation to social in...

Aviso de cookies: Usamos cookies propias y de terceros para mejorar nuestros servicios, para análisis estadístico y para mostrarle publicidad. Si continua navegando consideramos que acepta su uso en los términos establecidos en la Política de cookies.